| Description | Aprotinin (Traskolan) a broad-spectrum serine protease inhibitor, inhibiting the activity of a number of different esterases and proteases, including trypsin, chymotrypsin, kallikrein, plasmin, tissue plasminogen activator, and tissue and leukocytic proteinases. |
| In vitro | Aprotinin是一种抗纤溶分子，能够抑制胰蛋白酶和相关的蛋白水解酶。在细胞生物学中，aprotinin被用作酶抑制剂，以防止在细胞和组织的裂解或均质化过程中蛋白质降解。在aprotinin的存在下，纤溶活性被浓度依赖性地抑制，且凝血时间得以延长。Aprotinin是体外接触（内源性）凝血途径的有效抑制剂[2]。 |
| In vivo | Aprotinin 在体外可抑制凝块溶解，同时在体内可延长大鼠尾部出血时间及人类血浆的凝血时间。在大鼠动静脉分流模型中，aprotinin 能减轻血栓重量[2]。 |
| Cell experiments | Mouse G8-1 myoblasts are plated DMEM + 20% FBS (maintenance medium), in which they remain undifferentiated. When cells reach approximately 40-50% confluence, different protease inhibitors are added to the culture media and cells are incubated overnight. Cells are then switched to differentiation-promoting media (DMEM + 10% horse serum ± protease inhibitor) and incubated for 7 days. (Only for Reference) |
| Target activity | Trypsinogen:2 μM(Kd), Chymotrypsin:9.5 nM(Kd), Kallikrein:0.8 nM(Kd), Trypsin:0.06 pM(Kd) |
| Synonyms | 抑酶肽, 抑肽酶, Bovine Pancreatic Trypsin Inhibitor, Traskolan, Antilysin |
| molecular weight | 6511.51 |
| Molecular formula | C284H432N84O79S7 |
| CAS | 9087-70-1 |
| Storage | keep away from moisture|Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 100 mg/mL (15.36 mM), Sonication is recommended. |
| References | 1. Capasso C, et al. J Mol Recognit. 1997, 10(1):26-35. 2. Sperzel M, et al. J Thromb Haemost. 2007, 5(10):2113-2118. 3. James M. Wells, et al. Development. 1994, 120:3639-3647. 4. Jiang T Y, Feng X F, Fang Z, et al. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer[J]. Cancer Letters. 2020 5. Jiang T Y, Pan Y F, Wan Z H, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma[J]. Science Translational Medicine. 2020, 12(562). |
| Citations | 1. Jiang T Y, Pan Y F, Wan Z H, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. Science Translational Medicine. 2020, 12(562). 2. Jiang T Y, Feng X F, Fang Z, et al. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer. Cancer Letters. 2021, 501: 187-199. 3. Nie C, Zhou X A, Zhou J, et al.A transcription‐independent mechanism determines rapid periodic fluctuations of BRCA1 expression.The EMBO Journal.2023: e111951. |